FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 333 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... May 8, 2021 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 The Cancer Moonshot: Moving from Planning to Research November 19, 2018 Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... March 30, 2022 Load more HOT NEWS Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... A Clinical Signal of Efficacy Observed with a Combination of Nivolumab...
